ClinicalTrials.gg
RecruitingNCT06782724PsyPalUpdated May 8, 2026

Psilocybin Therapy for Psychological Distress in Palliative Patients

A Phase 2 interventional study of Psilocybin therapy in COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis) and MS (Multiple Sclerosis), sponsored by University Medical Center Groningen. Recruiting at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by University Medical Center Groningen · Phase 2, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies in Pulmonary Disease, Chronic Obstructive by University Medical Center Groningen — 6 open to participants now, 6 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · University Medical Center Groningen.

Planned enrollment
3rd of 14
108 · median 28
Started
2025
with 2 others
Phase 2
Only one
of the 28
Registered
27th of 28
by date

Among the 28 studies in Pulmonary Disease, Chronic Obstructive by University Medical Center Groningen, this one is the 3rd largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 2, and was the 27th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

6 of the 28 studies in Pulmonary Disease, Chronic Obstructive by University Medical Center Groningen are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Pulmonary Disease, Chronic Obstructive by University Medical Center Groningen, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether psilocybin therapy can effectively treat depression and psychological distress in adult patients with COPD, ALS, MS, or APD who have at least 6 months life expectancy. The main questions it aims to answer are:

  • Can psilocybin therapy safely reduce depressive symptoms compared to low-dose control?
  • Will the therapeutic effects be rapid and sustained over a 6-month period?

Researchers will compare patients receiving two escalating doses of psilocybin (15mg followed by 25mg) against those receiving two low doses (1mg) to see if the higher doses lead to greater improvements in depression, anxiety, demoralization, and quality of life.

Participants will:

  • Attend three preparation sessions with psychotherapists (1-2 hours each)
  • Undergo two supervised psilocybin dosing sessions (6-8 hours each)
  • Complete five integration therapy sessions following the dosing sessions
  • Participate in follow-up assessments at 6 weeks, 3 months, and 6 months
  • Have access to a digital care platform and peer support groups during the 6-month follow-up period
  • Optional: Control group participants may receive one high-dose psilocybin session (25mg) after the initial study period
Read the detailed description

Rationale Patients with chronic obstructive pulmonary disorder (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), or atypical and advanced Parkinsonian disorder (APD) often suffer from severe psychological distress with demoralization and death anxiety, which may culminate in to depressive disorder. Treatments of depression in palliative care currently involves psychotherapy and/or the use of antidepressants. However, these treatments have shown limited efficacy which urgently calls for new and innovative approaches. In recent years, a number of studies have shown very promising results of psilocybin therapy in alleviating psychological distress in patients with advanced cancer. The current study (PsyPal) aims to evaluate whether psilocybin therapy can also lead to rapid and sustained decreases in depressive symptoms, demoralization and other facets of psychological distress in patients who suffer from COPD, ALS, MS and APD.

Objective The primary objective of the PsyPal study is to assess the safety and efficacy of psilocybin therapy compared to low-dose control in reducing depressive symptoms in patients with COPD, ALS, MS, or APD. Secondary objectives of PsyPal are to assess change in clinical functioning, end-of-life anxiety, psychological/existential distress, health-related quality of life, and how it impacts caregiver 's health- and economic burden. The safety objective of PsyPal is to evaluate the difference in adverse events between high and low dose groups before, during and after the dosing session. Exploratory objectives include the investigation of psychological mechanism, subjective effects, biomarkers (EEG and blood-based), cost-effectiveness, and the usefulness of a digital care platform, with a mixed methods approach.

Main trial endpoints The main trial endpoint for PsyPal is the change in depression severity from baseline to 6 weeks after the second dose of psilocybin (high dose session). Adverse events and change in depression symptoms will also be assessed at 3- and 6-month follow-up to determine the safety and sustained effects of psilocybin therapy.

Secondary trial endpoints Secondary trial endpoints will be assessed at baseline and 6 weeks after the second dose of psilocybin. These include response rate, anxiety, demoralization, health-related quality of life, experiential avoidance, coping with illness, death anxiety, the wish to hasten death, self-compassion, spirituality, attachment, pain, healthcare resource use, blood-based biomarkers, and functional brain changes. Some secondary endpoints will also be assessed at the 3- and 6-month follow-up, including anxiety, demoralization, health-related quality of life, experiential avoidance, and coping with illness. These endpoints aim to improve our understanding of the effects of psilocybin therapy, how psilocybin therapy works, and to see which patients show the best response. Finally, changes in (religious/spiritual) beliefs/understandings and the experience(s) with psilocybin therapy will be assessed through in-depth qualitative interviews with patients that are conducted 6 weeks after the second dose of psilocybin.

Trial design PsyPal trial consists of a double-blind randomized low-dose controlled clinical trial with long term follow-up. Patients who are enrolled in the trial will be actively participating for ten weeks. After the primary endpoint, patients who received a low dose of psilocybin (1 mg) will be offered an optional single open label high-dose of psilocybin (25mg) together with three integration sessions. During long-term follow-up, patients will have access to a digital care platform and peer support groups.

Trial population The trial population in PsyPal consists of patients with COPD, ALS, MS, or APD and co-morbid depression. The main further inclusion criteria for participation are an age of 18 or higher, having an identified caregiver or support person, and a life expectancy of at least 6 months. The main exclusion criteria are current use of antipsychotic drugs, suicidal ideations, schizophrenia or other psychotic disorders, bipolar I/II disorder, other major neurological conditions, cardiovascular conditions, diabetes, and/or moderate to severe hepatic impairment (i.e., liver failure). Other exclusion criteria are a first-degree relative on the schizophrenia spectrum, other psychotic disorders, or bipolar I disorder.

Interventions

Patients will receive psilocybin therapy consisting of three phases; 1) preparation, 2) dosing, and 3) integration:

Preparation - The preparation phase consists of three psychotherapy sessions of 1-2 hours each. The purpose of these sessions is threefold: to build a therapeutic alliance between the patient and the therapist, to make a psychotherapeutic treatment plan for the patient using a process-based approach, and to educate patients about psilocybin's acute effects and how patients and therapists together can handle difficult experiences during the dosing sessions.

Dosing - The dosing phase of PsyPal starts 1-3 days after the last preparation session. It consists of two escalating dosing sessions of 6-8 hours each. The patient first receives a moderate dose of psilocybin (15mg). Two weeks later, the patient receives a high dose of psilocybin (25mg). Patients in the control group will receive two doses of psilocybin (1mg). All dosing sessions take place under supervision of two trained therapists within a treatment room specifically designed for psilocybin therapy and with a medical doctor on call.

Integration - The integration phase consists of five psychotherapeutic sessions of 1-2 hours each. There are two integration sessions following the first dosing session and three integration sessions following the second dosing session. The integration sessions are intended for further psychotherapeutic work, including working with the experience(s) that may have emerged during dosing sessions, and clinical assessment of the patient. Central topics may include the relationship with their life-limiting illness, death, meaning, sense of purpose, personal (religious/spiritual) beliefs, (social) relationships, and conflict resolution. The patient can also share thoughts and feelings about the PsyPal trial.

Long-term follow-up After the intervention, patients will be returned to regular care and followed for a period of 6 months, tracking usage of healthcare resources, the digital care platform, and peer support groups. Qualitative aspects of the intervention will be evaluated for patients, caregivers and therapists. Long-term safety data of psilocybin therapy will be collected for the four patient populations.

03

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)
  • ALS (Amyotrophic Lateral Sclerosis)
  • MS (Multiple Sclerosis)
  • Major Depressive Disorder (MDD)
  • Atypical Parkinson Disease

Keywords

  • psilocybin
  • therapy
  • palliative
  • care
  • palliative care
  • end-of-life distress
  • depression
  • psychological distress
  • psypal
  • copd
  • als
  • ms
  • apd
  • chronic obstructive pulmonary disorder
  • amyotrophic lateral sclerosis
  • multiple sclerosis
  • major depressive disorder
  • atypical parkinson disease
  • existential distress
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has to be diagnosed with one of the following four conditions, defined as:

    i) Diagnosis by medical specialist ii) Postbronchodilator /FVC \< 0,7 and FEV1 \<80% pred iii) ≥ 40 years old iv) ≥ 10 years smoking

    ALS i) ALS according to Goldcoast criteria (Shefner et al, Clin Neurophysiol, 2020) ii) ALS-FRS-R subscores of minimum 1 in item 2, 3 and 8, subscore of minimum 2 in item 1, 4 and 10 and a subscore of minimum 3 in item 11 and 12

    MS i) Fulfilled diagnostic revised McDonald criteria for MS from 2017 (Thompson et al., 2018) ii) EDSS ≥ 1,0

    APD i) Advanced to Late-Stage Parkinson's Disease - patients with a diagnosis of Parkinson's Disease per the MDS clinical diagnosis criteria with evidence of motor and non-motor fluctuations ii) Diseases in the spectrum of Progressive supranuclear palsy (PSP), fulfilling possible and probable criteria, according to the MDS diagnostic criteria iii) Clinically Established and Clinically Probable Multiple System Atrophy (MSA) according to the MDS diagnostic criteria

  2. Patient meets ICD-10 criteria for major depressive disorder documented through the com-pletion of the mood section of the Mini International Neuropsychiatric Interview by a screen-ing psychologist or physician.
  3. Patient has a MADRS score of > 19.
  4. Patient should have a of at least 6 months (assessed by study physician).
  5. Patient is at least 18 years of age.
  6. Patient has an identified caregiver/support person. See specific conditions for Czechia in Appendix 5.
  7. Patient is able to read and understand the and all scales used in a local language. For those with ALS, MS, or APD, competency is ensured via neurologist assessment, cognitive screening, caregiver support during screening and interactive approaches where the screening clinician ask the patient to explain their understanding of consent elements, re-explaining potentially misunderstood information.
  8. Patient is able to and willing to adhere to study requirements, including attending all study visits, preparatory and follow-up sessions, and completing all study evaluations.
  9. Patient is able to ingest capsules.

Exclusion criteria

Exclusion Criteria:

  1. Patient has used a psychedelic substance in the past 6 months (e.g., psilocybin, LSD, 5-MeO-DMT, DMT, ayahuasca or mescaline).
  2. Patient is in active treatments for other psychiatric disorders, judged by the screening clinician to be a more significant clinical problem than depression / distress.
  3. Patient meets ICD-10 criteria for schizophrenia spectrum or other psychotic disorders, including major depressive disorder with psychotic features (except substance/medication-induced or due to another medical condition) or bipolar I/II disorder.
  4. Patients with any lifetime diagnosis of schizophrenia spectrum or other psychotic disorders.
  5. Patient has a first-degree relative with schizophrenia spectrum, bipolar I disorder or other psychotic disorders (expect substance/medication-induced or due to another medical condition).
  6. Patients with a pre-existing psychiatric condition judged to be incompatible with safe exposure to psilocybin therapy.
  7. Significant suicide risk as defined by (1) suicidal ideation with intent to act (defined as ≥ 5 on MADRS item 10), (2) suicidal attempts within the past year, or (3) clinical assessment of significant suicidal risk during patient interview.
  8. Patient meets ICD-10 criteria for active/current alcohol or drug use disorder.
  9. Patient has ongoing treatment with antipsychotic drugs. Any prohibited agents must have been stopped at least 5x the elimination half-life of the specific drug at the time of baseline (see Appendix 1a for Prohibited medications).
  10. Patient is unwilling or unable to pause formal psychotherapy (days 0-42).
  11. Patient has neurological conditions (e.g., intracranial tumour, epilepsy, brain injuries, or other neurological disorders) expected by the PIs to conflict with the treatment / study protocol.
  12. Disease-specific exclusion criteria:

    : Unresolved exacerbation or pulmonary infection within last 4 weeks. ALS: Significant cognitive deficits (MoCa, see below). MS: Significant cognitive deficits (MoCa, see below), epilepsy or radiologically isolated syndrome.

    APD: Dementia (MoCa, see below), or Schwab and England ADL scale with scores > 80% in the best functional state.

  13. Cardiovascular conditions: recent stroke (\< 1 year from signing of ICF), recent myocardial infarction (\< 1 year from signing of ICF), uncontrolled hypertension (blood pressure > 140/90 mmHg), arrhythmia within 1 year of signing the ICF, or prolongation exceeding 450ms (males) / 470ms (females).
  14. Patient has moderate to severe hepatic impairment ( score ≥ 7).
  15. Patient has insulin-dependent diabetes or who are taking oral hypoglycaemic agents and have a current risk of hypoglycaemia that would require medical intervention.
  16. Patient has any physical or psychological symptoms, medications, blood test results or clinically significant findings at Screening or Baseline (based on the clinical judgement of clinical/medical study personnel) that would make a patient unsuitable for the study.
  17. Patient has an allergy or intolerance to any of the materials contained in either drug product.
  18. Cognitive and Neuropsychological assessment: Patients will be excluded if they score below mean minus 1.5 Standard Deviation according to normative age and scholarity adjusted data on the (MoCA) assessment.
  19. Recent (2 weeks) change or planned change in antidepressant medication during the intervention.
  20. Women who are pregnant, intend to become pregnant during the study or who are currently nursing, or are unwilling to use Highly Effective Methods
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Moderate (15mg) and high dose (25mg) psilocybin group

    Patients assigned to this arm will first receive three prepration sessions followed by one moderate dose (15mg) of psilocybin. Patients will then receive two integration sessions and a high dose (25mg) of psilocybin. This is followed by three integration sessions.

    Drug: Psilocybin therapy

  • Placebo comparator
    Low-dose (1mg) psilocybin group

    Patients assigned to this arm will first receive three prepration sessions followed by one low dose (1mg) of psilocybin. Patients will then receive two integration sessions and another low dose (1mg) of psilocybin. This is followed by three integration sessions.

    Drug: Psilocybin therapy

Interventions

  • DrugPsilocybinStudies of PsilocybinPsilocybin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Psilocybin therapy consisting of three preparation, two dosing, and three integration sessions. All sessions will take place in a controlled, safety environment and supported by two study therapists

06

What researchers measure

Primary outcomes

  1. Depressive symptoms (MADRS)

    To examine medium/high-dose psilocybin therapy safety and efficacy in reducing symptoms of depression in patients with COPD, ALS, MS, or APD, compared to the low-dose control group.

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

Secondary outcomes

  1. Response rate

    To determine the response rate to psilocybin therapy (≥50% reduction in MADRS)

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  2. End-of-life anxiety

    To evaluate the effect of psilocybin therapy on end-of-life anxiety \- Death and Dying Distress Scale (DADDS)

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  3. Anxiety and depression (symptoms)

    To evaluate the effect of psilocybin therapy on symptoms of anxiety and depression \- Hospital Anxiety and Depression Scale (HADS)

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  4. Demoralization

    To assess the impact of psilocybin therapy on demoralization \- Demoralization Scale-II (DS-II)

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  5. Impact on Quality of life

    To evaluate the effect of psilocybin therapy on quality of life \- EQ-5D-5L

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  6. Caregiver burden

    To assess the impact of psilocybin therapy on caregiver burden \- Zarit Burden Interview (ZBI-7)

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  7. Daily functioning in COPD

    To assess the impact of psilocybin therapy on daily function in patients with COPD. \- CODP Assessment Test (CAT)

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  8. Health-related quality of life in COPD

    To assess the impact of psilocybin therapy on health-related quality of life in patients with COPD. \- St. George's Respiratory Questionnaire (SGRQ-C)

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  9. Health-related quality of life in ALS

    To assess the impact of psilocybin therapy on quality of life in patients with ALS. \- Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALS-AQ-5)

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  10. Functional status in ALS

    To assess the impact of psilocybin therapy on functional status in patients with ALS \- ALS Functional Rating Scale Revised (ALS-FRS-R)

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  11. Health-related quality of life in MS

    To assess the impact of psilocybin therapy on health-related quality of life in patients with MS. \- Expanded Disability Status Scale (EDSS)

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  12. Health-related quality of life in APD

    To assess the impact of psilocybin therapy on health-related quality of life in patients with APD. \- Parkinson's Disease Questionnaire (PDQ-8)

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  13. Motor and non-motor symptoms in APD

    To assess the impact of psilocybin therapy on (non-)motor symptoms in patients with APD. \- Movement Disorders Society Unified Parkinson Disease Rating Scale (MDS-UPDRS, parts I, II, and III)

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  14. Functional magnetic resonance imaging (fMRI) in APD

    At the Champalimaud Foundation in Lisbon, structural and functional magnetic resonance imaging (MRI) will be conducted in patients with APD. Changes in brain volume and tissue microstructures (with fractional anisotropy and diffusivity) will be computed. Changes in whole brain resting-state functional connectivity will be additionally computed using the BOLD response. The structural and function MRI protocol consists of 3D T1-weighted, T2/PD-weighted, FLAIR, T2\*, diffusion tensor, and blood-oxygen-level-dependent (BOLD) imaging.

    Time frame: Baseline (Day -14) to one week after Dose 2 (Day 21)

  15. Incidence, severity, and frequency of (serious) adverse events following psilocybin therapy

    The reporting of (serious) adverse events by using MedDRA version 27.0 during the clinical trial.

    Time frame: Baseline (Day -14), Dose 1 (Day 0), Integration 1 (Day 1), Integration 2 (Day 7), Dose 2 (Day 14), Integration 3 (Day 15), Integration 4 (Day 21), Integration 5 (Day 28), Primary endpoint (Day 56), Open label dose (Day 62), 3- and 6-month follow-up

Other outcomes

  1. Experiential avoidance

    To assess the impact of psilocybin therapy on experiential avoidance \- Brief Experiential Avoidance Questionnaire (BEAQ)

    Time frame: Baseline to Primary Endpoint (Day 56)

  2. Coping

    To assess the impact of psilocybin therapy on coping with a chronic illness \- BRIEF-COPE questionnaire

    Time frame: Baseline to Primary Endpoint (Day 56)

  3. The wish to hasten death

    To assess the impact of psilocybin therapy on the wish to hasten death \- Scheduled Attitudes towards Hastened Death (SAHD)

    Time frame: Baseline to Primary Endpoint (Day 56)

  4. Self-compassion

    To assess the impact of psilocybin therapy on self-compassion \- Self-Compassion Scale Short-Form (SCS-SF)

    Time frame: Baseline to Primary Endpoint (Day 56)

  5. Attachment

    To assess the impact of psilocybin therapy on attachment \- Experientience in Close Relationships (ECR)

    Time frame: Baseline to Primary Endpoint (Day 56)

  6. Pain perception

    To assess the impact of psilocybin therapy on pain perception \- Numeric Rating Scale

    Time frame: Baseline to Primary Endpoint (Day 56)

  7. Spiritual well-being

    To assess the impact of psilocybin therapy on spiritual well-being \- Functional Assessment of Chronic Illness Therapy - Spiritual well-being 12 (FACIT-Sp-12)

    Time frame: Baseline to Primary Endpoint (Day 56)

  8. Mystical experience

    To assess whether psilocybin induces a mystical experience using the Mystical Experience Questionnaire (MEQ-30) and explore how it relates to antidepressant efficacy and other related outcome measures (e.g., anxiety, death anxiety, demoralization).

    Time frame: Dosing session 1 (Day 0) and Dosing session 2 (Day 14)

  9. Emotional breakthrough

    To assess whether psilocybin results in an emotional breakthrough using the Emotional Breakthrough Inventory (EBI) and explore how it relates to antidepressant efficacy and other related outcome measures (e.g., anxiety, death anxiety, demoralization).

    Time frame: Dosing session 1 (Day 0) and Dosing session 2 (Day 14)

  10. Challenging experiences

    To assess whether psilocybin induces challenging experiences using the Challenging Experience Questionnaire (CEQ) and explore how it relates to antidepressant efficacy and other related outcome measures (e.g., anxiety, death anxiety, demoralization).

    Time frame: Dosing session 1 (Day 0) and Dosing session 2 (Day 14)

  11. Experience of music during dosing sessions

    To assess how study participants experience during the dosing session and explore how it relates to antidepressant efficacy and other related outcome measures (e.g., anxiety, death anxiety, demoralization).

    Time frame: Dose 1 (Day 0) and Dose 2 (Day 14)

  12. Brain function

    To assess whether there are changes in prefrontal theta activity following psilocybin therapy brain using electroencephalogrphy (EEG) in patients with COPD and MS. Time-frequency analyses will be conducted and various ERP components will be examined, particularly the LPP, N2b, and P300. Other exploratory measures include frontal alpha asymmetry, frontoparietal alpha and theta power, ECG-derived average heart rate and heart rate variability occipital alpha asymmetry, parieto-occipital alpha power, Lempel-Ziv Complexity, and State-Space Entropy . The EEG assessments include a resting-state scan (10 minutes) and an emotional reactivity scan (10 minutes), where patients are presented with neutral (n=24), negative (n=24), and positive (n=24) stimuli. Each stimulus is presented for 2 seconds followed by a question about the emotional intensity.

    Time frame: Baseline (Day -14), one day after Dose 1 (Day 1), and one day after Dose 2 (Day 15)

  13. Blood-based biomarkers

    To assess whether there are changes in blood-based biomarkers following psilocybin therapy by using serum and plasma analysis of several different neuroendocrine (cortisol, prolactin, oxytocin, ACTH), inflammatory (CRP, IL-1 beta, IL-6, and TNF-alpha), neurotrophic (brain-derived neurotrophic factor and Val66Met), and neurological (neurofilaments) biomarkers. Gene expression in intracellular RNA in whole blood will also be analyzed as well as psilocin concentration in plasma during dosing sessions.

    Time frame: Baseline (Day -14) to Dose 2 (Day 14) and primary endpoint (Day 56)

  14. Cost-effectiveness

    To evaluate the cost-effectiveness of psilocybin therapy, taking into account health gains for patients and caregivers as well as costs of the therapy and use of societal resources.

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  15. Long-term positive and negative effects

    To monitor long-term positive and negative effects of psilocybin therapy through the evaluation of quantitative and qualitative methods

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56) and 3-month (Day 104) and 6-month follow-up (Day 194)

  16. Verbal learning and memory in APD

    To assess the impact of psilocybin therapy on verbal learning and memory in patients with APD. \- Rey Auditory Verbal Learning Test

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  17. Working memory and attention in APD

    To assess the impact of psilocybin therapy on working memory and attention in patients with APD. \- Letters and Numbers Sequence

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  18. Cognitive flexibility in APD

    To assess the impact of psilocybin therapy on cognitive flexibility in patients with APD. \- Trail Making Test

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  19. Executive function, lexical retrieval, and processing speed in APD

    To assess the impact of psilocybin therapy on executive function, lexical retrieval, and processing speed in patients with APD. \- Verbal Fluency

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  20. Sustained attention and working memory in APD

    To assess the impact of psilocybin therapy on attention and working memory in patients with APD. \- Digit Span

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  21. Processing speed, working memory, sustained attention, visual-motor coordination, and executive function in APD

    To assess the impact of psilocybin therapy on processing speed, working memory, sustained attention, visual-motor coordination, and executive function in patients with APD. \- Digit Symbol Substitution Test

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  22. Reading skills in APD

    To assess the impact of psilocybin therapy on reading skills in patients with APD. \- Irregular Word Reading Test

    Time frame: Baseline (Day -14) to Primary Endpoint (Day 56)

  23. Optional: qualitative interviews (patients)

    Online or in-person semi-structured interviews to explore lived experiences of psilocybin therapy in patients with COPD, ALS, MS, or APD.

    Time frame: After Primary Endpoint (Day 56)

  24. Optional: focus group (patients)

    Online focus groups to exchange experiences of psilocybin therapy with peers

    Time frame: At the end of Long-Term Follow-Up (Day 194)

  25. Optional: journaling (patients)

    Patient are asked to reflect on their experience with psilocybin therapy through a journal during the clinical trial.

    Time frame: Continuous during clinical trial

  26. Optional: focus groups (therapists)

    Online focus groups with therapists to explore their perspective on psilocybin therapy

    Time frame: At the end of Long-Term Follow-Up (Day 194)

  27. Optional: journaling (therapists)

    Therapists are asked to reflect on their experience with psilocybin therapy through a journal during the clinical trial.

    Time frame: Baseline to 3-month and 6-month follow-up

  28. Optional: focus group (caregivers)

    Online focus groups with caregivers to explore their perspective on psilocybin therapy.

    Time frame: After Primary Endpoint (Day 56) and at the end of Long-Term Follow-Up (Day 194)

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.

Of 47 non-industry phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's planned 18 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 20, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2028
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06782724
Collaborators
HumanKindLabs, University of Copenhagen, CTC Clinical Trial Consultants AB, OPEN Foundation, IESE Business School, Uppsala University, The Champalimaud Centre, Lisbon, Portugal, Stockholm University, University of Groningen, The Netherlands, National Institute of Mental Health, Czech Republic, European Association for Palliative Care, Madopa, Bispebjerg Hospital, European Association of Neurological Associations (EFNA), 29k International AB, Lung Alliance Netherlands, European Psychiatric Association, Norrsken Mind
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
Jul 1, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
May 8, 2026

Study contacts

Robert A Schoevers, Professor
Contact
r.a.schoevers@umcg.nl
050 361 2008

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion